QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) Stock Forecast, Price & News

$16.70
-0.05 (-0.30 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.70
Now: $16.70▼
$16.70
50-Day Range
$16.75
MA: $19.39▼
$20.13
52-Week Range
$15.63
Now: $16.70▼
$30.00
Volume646 shs
Average Volume523 shs
Market Capitalization$5.01 billion
P/E Ratio15.05
Dividend YieldN/A
Beta0.68
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Headlines

Swedish Orphan Biovitrum AB (publ) 2020 Q4 - Results - Earnings Call Presentation
February 18, 2021 |  seekingalpha.com
Sobi publishes report for the fourth quarter and full-year 2020
February 18, 2021 |  finance.yahoo.com
Kineret® (anakinra) approved in Russia for the treatment of CAPS
February 16, 2021 |  finance.yahoo.com
FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)
December 22, 2020 |  finance.yahoo.com
Sobi appoints new Head of North America ahead of launch phase
December 21, 2020 |  finance.yahoo.com
Doptelet® (avatrombopag) receives positive opinion from CHMP for treatment of ITP
December 11, 2020 |  finance.yahoo.com
Emapalumab submission in China for primary HLH
December 10, 2020 |  finance.yahoo.com
Realising opportunities for future growth and financial update: Sobi Capital Markets Day 2020
December 10, 2020 |  feeds.benzinga.com
Agenda: Sobi Capital Markets Day 2020
December 7, 2020 |  finance.yahoo.com
Swedish Orphan Biovitrum AB
November 25, 2020 |  wsj.com
Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
November 19, 2020 |  finance.yahoo.com
Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan
November 19, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers—Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BIOVF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.sobi.com
Phone46-8697-2000
Employees1,509
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.57
Current Ratio0.78
Quick Ratio0.42

Price-To-Earnings

Trailing P/E Ratio15.05
Forward P/E Ratio18.98
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.51 billion
Price / Sales3.32
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)$1.25
Net Income$349.56 million
Net Margins19.77%
Return on Equity17.14%
Return on Assets7.00%

Miscellaneous

Outstanding Shares299,978,000
Market Cap$5.01 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.91 out of 5 stars

Medical Sector

1070th out of 1,958 stocks

Drug Manufacturers—Specialty & Generic Industry

19th out of 62 stocks

Analyst Opinion: 0.0Community Rank: 1.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -
$16.70
-0.05 (-0.30 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIOVF News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOVF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Frequently Asked Questions

Is Swedish Orphan Biovitrum AB (publ) a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Swedish Orphan Biovitrum AB (publ) stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOVF, but not buy additional shares or sell existing shares.
View analyst ratings for Swedish Orphan Biovitrum AB (publ) or view top-rated stocks.

What stocks does MarketBeat like better than Swedish Orphan Biovitrum AB (publ)?

Wall Street analysts have given Swedish Orphan Biovitrum AB (publ) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Swedish Orphan Biovitrum AB (publ) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 798,700 shares, an increase of 34.6% from the January 14th total of 593,200 shares. Based on an average daily volume of 800 shares, the days-to-cover ratio is presently 998.4 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest.

When is Swedish Orphan Biovitrum AB (publ)'s next earnings date?

Swedish Orphan Biovitrum AB (publ) is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Swedish Orphan Biovitrum AB (publ).

How has Swedish Orphan Biovitrum AB (publ)'s stock price been impacted by COVID-19 (Coronavirus)?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $20.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOVF shares have decreased by 16.5% and is now trading at $16.70.
View which stocks have been most impacted by COVID-19.

Who are Swedish Orphan Biovitrum AB (publ)'s key executives?

Swedish Orphan Biovitrum AB (publ)'s management team includes the following people:
  • Dr. Guido Oelkers, CEO & Pres (Age 56)
  • Mr. Henrik Stenqvist, Chief Financial Officer (Age 54)
  • Dr. Ravi Madduri Rao Ph.D., Head of R&D and Chief Medical Officer (Age 53)
  • Ms. Anne Marie de Jonge Schuermans, Head of Technical Operations (Age 49)
  • Ms. Paula Treutiger, Head of Corp. Communications & Investor Relations (Age 54)
  • Mr. Torbjörn Hallberg, Gen. Counsel and Head of Legal Affairs & HR (Age 52)
  • Ms. Annika Muskantor, Head of Global Supply Chain (Age 55)
  • Mr. Jorgen L. Winroth, Sr. IR Advisor
  • Mr. Philip Wood, Head of Haematology (Age 53)
  • Mr. Bruce Faulkner-Dunkley, Global Head of L&OD

Who are some of Swedish Orphan Biovitrum AB (publ)'s key competitors?

Some companies that are related to Swedish Orphan Biovitrum AB (publ) include Canopy Rivers (RIV), Liberty Health Sciences (LHSIF), Qilian International Holding Group (QLI), Willow Biosciences Inc. (WLLW.TO) (WLLW), XPhyto Therapeutics (XPHYF), MediPharm Labs Corp. (LABS.TO) (LABS), Khiron Life Sciences Corp. (KHRN.V) (KHRN), Delta 9 Cannabis (DN), Jupiter Wellness (JUPW), FSD Pharma (HUGE), Meta Growth Corp. (META.V) (META), 48North Cannabis Corp. (NRTH.V) (NRTH), (CSI) (CSI), (IMCC) (IMCC) and 1933 Industries (TGIFF).
View all of BIOVF's competitors.

What is Swedish Orphan Biovitrum AB (publ)'s stock symbol?

Swedish Orphan Biovitrum AB (publ) trades on the OTCMKTS under the ticker symbol "BIOVF."

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Swedish Orphan Biovitrum AB (publ)'s stock price today?

One share of BIOVF stock can currently be purchased for approximately $16.70.

How much money does Swedish Orphan Biovitrum AB (publ) make?

Swedish Orphan Biovitrum AB (publ) has a market capitalization of $5.01 billion and generates $1.51 billion in revenue each year. The company earns $349.56 million in net income (profit) each year or $1.25 on an earnings per share basis.

How many employees does Swedish Orphan Biovitrum AB (publ) have?

Swedish Orphan Biovitrum AB (publ) employs 1,509 workers across the globe.

What is Swedish Orphan Biovitrum AB (publ)'s official website?

The official website for Swedish Orphan Biovitrum AB (publ) is www.sobi.com.

Where are Swedish Orphan Biovitrum AB (publ)'s headquarters?

Swedish Orphan Biovitrum AB (publ) is headquartered at Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76.

How can I contact Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ)'s mailing address is Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76. The company can be reached via phone at 46-8697-2000 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.